Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations

Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations


The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020.

Mike Blake | Reuters

A Delaware federal court jury on Tuesday cleared Gilead Sciences of civil claims by the U.S. government that the company violated patents held by the Centers for Disease and Prevention for an HIV prevention drug.

The government sued Gilead in 2019, arguing that the company was profiting off CDC patents through the company’s sales of Truvada and Descovy, oral medications taken to prevent HIV infection.

But jurors after a multi-day trial found that the government’s patent claims on the HIV prevention regimen called pre-exposure prophylaxis, or PrEP, were not valid.

“Today’s decision confirms our longstanding belief that we have always had the rights to make Truvada and Descovy for PrEP available to all who need it,” said Gilead general counsel Deb Telman in a statement.

“Gilead will continue to champion collaborations, including our efforts with the U.S. Health and Human Services Department (HHS) and CDC that span more than 15 years, as we all work together toward our common goal to end the HIV epidemic for everyone, everywhere,” Telman said.

HHS, the parent entity of CDC, did not immediately respond to a request for comment on the verdict.

Gilead’s combined worldwide sales of Truvada and Descovy were about $2 billion in 2022, according to company financial statements.

The government claimed that the CDC in the mid-2000s discovered that two drugs, emtricitabine and tenofovir, were highly effective in preventing HIV infection.

Truvada and Descovy both contain emtricitabine and tenofovir. But Gilead said it invented these drugs, and that the concept of using Truvada to prevent HIV was well known when the U.S. government filed for the patents.

PrEP has played a crucial role in reducing the number of new HIV infections in communities that face a higher risk from the virus, such as men who have sex with other men.

Scientists have tried for decades to develop a vaccine against HIV. But those efforts to date have been unsuccessful.

About 40 million people worldwide have died from HIV since the epidemic began in the 1980s, according to the World Health Organization. More than 80 million people have been infected.

In 2021, there were 38 million people living with HIV, according to the WHO data.



Source

Kimberly-Clark agrees to buy Tylenol owner Kenvue in .7 billion deal, creating consumer staples giant
Business

Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant

Huggies, manufactured by Kimberly-Clark and Band-Aid, manufactured by Kenvue. Getty Images Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at $48.7 billion that would create a consumer staples giant. The deal is a combination of cash and stock. Shares of Kenvue surged 20% in premarket trading Monday, while shares […]

Read More
Where the blockbuster weight loss drug market stands today — and what’s coming next
Business

Where the blockbuster weight loss drug market stands today — and what’s coming next

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied.  From fresh competition to new uses, the market is quickly vaulting into a new stage of […]

Read More
Just 5% of CRE companies have achieved their AI goals. Here’s why
Business

Just 5% of CRE companies have achieved their AI goals. Here’s why

Diminishing perspective of downtown London skyscrapers Chunyip Wong | Istock | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large […]

Read More